Select Page

Catalyst’s Plan for Amifampridine phosphate® NDA

Robert Gadimian from www.hotbiotechstocks.com explains Catalyst’s plan for amifampridine phosphate NDA in Lambert-Eaton Myasthenic Syndrome (LEMS). Introduction Catalyst Pharmaceuticals Inc. (Nasdaq:CPRX) focuses on developing innovative therapies for people with rare...